Mazdutide
Mazdutide is a peptide, indexed here under Incretin receptor agonists.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Incretin receptor agonists |
| CAS registry number | 2259884-03-0[1] |
| PubChem CID | 167312357[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C207H317N45O65[1] |
| Molecular weight | 4476 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Mazdutide, development codes IBI362 and LY3305677, is described in the retrieved literature as a GLP-1 and glucagon receptor dual agonist. A 2021 EClinicalMedicine paper and a 2022 Nature Communications phase 1b randomised trial report it in Chinese adults with overweight or obesity, and a 2022 EClinicalMedicine paper reports the 9 mg and 10 mg doses in the same population.
Later records are phase 2 and phase 3 trials. A 2023 Nature Communications paper reports a phase 2 randomised controlled trial, a 2024 Diabetes Care paper reports a randomised double-blind placebo-controlled trial in Chinese patients with type 2 diabetes, a 2025 New England Journal of Medicine paper reports once-weekly administration in Chinese adults with obesity or overweight, and two 2026 Nature papers report comparisons against placebo and against dulaglutide in type 2 diabetes. A 2024 Frontiers in Endocrinology paper is a systematic review and meta-analysis of weight endpoints.
[3, 4, 5, 6, 7, 8, 9, 10, 11]Reported mechanism
A GLP-1 receptor and glucagon receptor dual agonist, per the retrieved records.
[5, 4]Stated in the titles of the cited 2022 EClinicalMedicine and 2022 Nature Communications papers.
Targets named in the cited records: GLP-1 receptor, glucagon receptor.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Mazdutide appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- IBI362
- LY3305677
Where this page sits
Research records
Cited research records for Mazdutide, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Side-by-side pages that include Mazdutide
Compounds indexed next to it
- Survodutide — Incretin receptor agonists
- Tirzepatide — Incretin receptor agonists
Named targets in the cited records
Class page: Incretin receptor agonists. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Mazdutide?
Mazdutide, development codes IBI362 and LY3305677, is described in the retrieved literature as a GLP-1 and glucagon receptor dual agonist. A 2021 EClinicalMedicine paper and a 2022 Nature Communications phase 1b randomised trial report it in Chinese adults with overweight or obesity, and a 2022 EClinicalMedicine paper reports the 9 mg and 10 mg doses in the same population.
Which class is Mazdutide indexed under?
Mazdutide is indexed under Incretin receptor agonists. Incretin receptor agonists are synthetic peptides that bind one or more of the incretin and glucagon family receptors, principally the glucagon-like peptide-1 receptor.
What does the FDA application register show for Mazdutide?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 167312357, Mazdutide. PubChem, National Library of Medicine (2026). pubchem:167312357
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:mazdutide
- IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study. EClinicalMedicine (2021). pmid:34430840
- A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nature communications (2022). pmid:35750681
- Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine (2022). pmid:36247927
- A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nature communications (2023). pmid:38092790
- Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Diabetes care (2024). pmid:37943529
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. The New England journal of medicine (2025). pmid:40421736
- Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature (2026). pmid:41407859
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature (2026). pmid:41407860
- Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Frontiers in endocrinology (2024). pmid:38440786
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.